Copyright ©The Author(s) 2016.
World J Gastroenterol. Aug 7, 2016; 22(29): 6638-6651
Published online Aug 7, 2016. doi: 10.3748/wjg.v22.i29.6638
Table 1 Proposed treatment regimen(s) with rifaximin by indication
DisorderEvidence of beneficial effectRecommended regimenRef.
IBSRandomized controlled multicenter studies show improvement in global IBS symptoms400-550 mg three times daily for 2 wk May require intermittent retreatment[87,88]
Treatment of TDRandomized controlled trials show reduced duration of the illness200 mg three times daily for 3 d[94,95]
Prevention of TDRandomized controlled trials in patients traveling to south and southeast Asia; and Mexico200 mg twice daily or 600 mg daily while in high risk area[97,98]
SIBORifaximin normalizes the hydrogen breath test and improves symptoms400 mg three times daily for 2 wk May require retreatment[99-101]
Hepatic encephalopathyRandomized controlled trials, proved efficacy and safety550 mg 2 or 3 times daily chronically[104-106]
Diverticular diseaseRandomized controlled trials showed that rifaximin improves symptoms and prevents recurrence400 mg twice daily for 7 d every month[110-115]
IBD and pouchitisObservational data and small pilot studies Retrospective study400-800 mg twice daily for 12 wk May require retreatment or intermittent treatment 400 mg three times daily chronically[125-129] [136]
SBP prophylaxis
Recurrent Clostridium difficile infectionSmall case series and retrospective studies400 mg twice daily for 2 wk[140-142]